NAD+

A coenzyme central to energy metabolism, DNA repair, and cellular signaling

Overview

NAD+ is not a peptide. Nicotinamide Adenine Dinucleotide is its full name, and the molecule is built from two nucleotides joined to each other. Listing it on the site alongside the research-molecule pages is reasonable, but scientifically it should never be called 'the peptide NAD+'. Present in all cells, NAD+ takes part in two broad kinds of activity. The first is electron transfer within energy-production processes: NAD+ is the oxidized form, and on accepting electrons and hydrogen it becomes NADH, while the ratio between the two shapes glycolysis, the Krebs cycle, the respiratory chain and further metabolic pathways. The second is its service as a substrate for enzymes — among them the Sirtuins, the PARP proteins involved in the response to DNA damage, and the enzyme CD38, which takes part in cellular signaling and in the breakdown of NAD+. When those enzymes consume NAD+, the molecule is not merely carrying electrons; it is broken down as part of the biological reaction [1-3]. Research interest in NAD+ widened after studies tied NAD balance to mitochondrial function, inflammation, cellular stress and aging. Most of the strong findings on age-related decline, and on improvement once NAD is raised, come from animals; the human data are more complex and vary with the tissue, the population and the measurement method. (PubMed)

Biological Mechanism

During energy production NAD+ takes up electrons from molecules being broken down inside the cell and turns into NADH. NADH can then pass those electrons to the respiratory chain in the mitochondria, where they help build a proton gradient and produce ATP. None of this means that more NAD+ always leads to more energy: mitochondrial activity also hinges on oxygen, nutrient availability, enzyme function, the NAD+/NADH ratio and the state of the cell as a whole [1]. The Sirtuin family draws on NAD+ for deacetylation reactions that touch proteins related to metabolism, damage repair and the stress response. PARP enzymes use it to build ADP-ribose chains when DNA damage has to be answered. The enzyme CD38 breaks NAD+ down and yields signaling molecules connected, among other things, to calcium and to immune function [2,3]. Mouse studies have shown CD38 activity rising with age and contributing both to a decline in NAD levels in tissues and to changes in mitochondrial function. A further study proposed a chain linking the accumulation of senescent cells, the secretion of inflammatory signals, an increase in CD38-expressing macrophages and a decline in NAD in the liver and adipose tissue [2,3]. That model offers a plausible route by which inflammation and cellular aging shape NAD balance. It does not establish that every older adult has a systemic 'NAD+ deficiency', and it does not establish that raising NAD artificially will change the aging process as a whole. (PubMed)

Research Evidence

Preclinical work on the NAD system is broad, spanning models of metabolism, muscle, brain, inflammation and aging. In some of those models, raising NAD through precursors or curbing the activity of the enzymes that consume it improved metabolic and functional measures. Such results helped launch human research, yet they should not be taken as proof of an identical effect in humans. Nor is the assumption that NAD+ levels decline uniformly with age in humans fully established. Earlier studies reported a decline in some tissues and samples, while a study published in Nature Metabolism in 2026 measured NAD+ in whole blood across seven human cohorts and found the levels holding relatively stable across age and across several lifestyle interventions; the researchers concluded that the whole-blood NAD+ level is not necessarily a good marker of aging [4]. This is not an absolute contradiction of the tissue studies in animals. Whole blood, muscle, liver, brain and adipose tissue are different biological compartments, and red blood cells hold a large metabolic pool capable of masking changes occurring elsewhere. What the finding does is sharpen the need to specify which tissue was measured and by which method, rather than invoking 'the NAD level in the body' as though it were a single uniform number. (PubMed)

How NAD+, NADH, NR and NMN Differ

Several distinct molecules often get folded into one discussion of NAD. NADH is the reduced form of NAD+, whereas NR and NMN are precursors the body can feed into NAD-synthesis pathways. Metabolic kinship notwithstanding, these are not the same substance and they do not share the same pharmacokinetics. A randomized study in middle-aged and older adults found that Nicotinamide Riboside, or NR, raised the blood NAD metabolome and was well tolerated during the study period [5]. In another controlled study, this one in 12 older men, NR raised NAD-related metabolites in muscle without improving the mitochondrial bioenergetics that were measured [6]. A randomized study in postmenopausal women with prediabetes and overweight found that NMN improved insulin sensitivity in muscle along with certain signaling pathways, with no matching improvement across all glucose measures or across all organs [7]. Valuable as these studies are for understanding the NAD system, none of them is direct evidence about NAD+ infusion. A precursor that is ingested and then metabolized in the gut, liver and tissues is not equivalent to the NAD+ molecule located outside the cells. Even two substances that both raise an NAD-related marker may differ in duration of activity, in distribution and in functional outcomes. (PubMed)

Direct Evidence on IV NAD+

The human literature on NAD+ infusion itself is far thinner than the literature on NR and NMN. A pilot study from 2019 followed NAD+ and its metabolites in plasma and urine through a prolonged infusion, with the aim of describing metabolism and clearance rather than testing treatment of aging, fatigue, cognition or a specific disease [1]. Over the first hours there was no simple, immediate rise in plasma NAD+ in proportion to the amount administered. Changes in NAD and related metabolites appeared later, together with urinary excretion, which suggests that part of the substance is broken down or rapidly metabolized before it appears in the blood as an intact NAD+ molecule. The study was small and shows neither which tissues the substance reached nor whether a clinical benefit was produced [1]. A small retrospective study published in 2026 examined real-world data on NAD+ and NR infusions in a commercial setting; among NAD+ recipients it documented gastrointestinal symptoms, increased heart rate, chest pressure and discomfort during the infusion. Being non-randomized, without a placebo and based on a small number of records, it offers preliminary information on tolerability rather than proof of efficacy or a full safety profile [8]. (PubMed)

NAD+, Aging and Outcome Measures

Measuring NAD is not enough for aging research. Even where an intervention lifts NAD+ in the blood or metabolites in muscle, the open question remains whether anything has changed in mitochondrial function, insulin sensitivity, strength, endurance, cognition, morbidity or quality of life. Aging encompasses DNA damage, epigenetic changes, chronic inflammation, impaired communication between cells, changes in proteins, a decline in stem-cell function and changes in mitochondria. NAD+ connects to several of those axes without controlling the system on its own, so describing it as an 'anti-aging molecule' stretches the conclusions past the evidence. The direction of causality is not always clear either. A lower level of NAD in a diseased tissue may be participating in the disease, but it may equally be a result of inflammation, cellular damage or a change in cell composition — and raising the marker is no guarantee that the primary cause has been corrected. (PubMed)

Safety, Sterility & Endotoxins

Assessing the safety of an injectable NAD+ product goes well beyond the identity of the molecule. A sterile product has to satisfy requirements covering raw material, sterility, endotoxins, particulates, concentration, stability and storage, and material intended for food or a supplement is not automatically suitable for preparing a sterile product. In October 2024 the FDA reported on the use of food-grade NAD+ raw material to prepare intravenous products. Reports reached the agency of severe chills, tremor, vomiting and fatigue, with some patients requiring medical care, and the reaction was described as consistent with exposure to high levels of endotoxins [9]. In a warning letter from January 2026 the FDA described an event in which three people were referred to the emergency room after receiving an NAD+ product from the same batch; in testing of a sealed vial an endotoxin level of 3,360 EU per mL was found [10]. None of this proves that every reaction to an NAD+ infusion is caused by endotoxins, or that the molecule itself necessarily causes the same reaction. What these events show is that a difference in raw-material quality and in production control can change the risk substantially, and that a contaminated product leaves the safety of pure NAD+ impossible to assess. (U.S. Food and Drug Administration)

Translation Limitations & Quality Metrics

One leading limitation in this field is the habit of treating a rise in NAD as a medical effect. A study showing an increase in a metabolite after NR does not prove an improvement in function, and a study on NMN does not prove that an NAD+ infusion would deliver the same result. Measurement in the blood, likewise, does not necessarily reflect the liver, the muscle or the brain. Precision about the substance under test is equally necessary: NAD+ can undergo breakdown, hydrolysis and oxidation, and measuring it is sensitive to the manner of sample collection, the time until freezing and the laboratory method. A final product calls for testing of identity, concentration, degradation products, sterility and endotoxins. Future research on NAD+ itself should carry a control group, blinding, functional outcomes and safety monitoring; without those components it is hard to pull apart genuine biochemical activity, an expectation response, the effect of the infusion fluids and short-term changes that are not maintained.

Summary

NAD+ is a coenzyme central to energy transfer, cellular signaling and the activity of enzymes involved in DNA repair and the stress response [1-3]. Studies connect NAD levels, inflammation and aging, yet the human data are inconsistent, and the direct evidence on infusion amounts to small studies set alongside safety, sterility and endotoxin issues [2-10]. The substance is intended for laboratory research use only.

Selected Research Sources

1. Grant R. et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a Six-Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience, 2019. PMID: 31572171
2. Camacho-Pereira J. et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism, 2016. PMID: 27304511
3. Covarrubias A.J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism, 2020. PMID: 33199924
4. Trętowicz M.M. et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nature Metabolism, 2026. PMID: 42135539
5. Martens C.R. et al. Chronic nicotinamide riboside supplementation is well tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 2018. PMID: 29599478
6. Elhassan Y.S. et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports, 2019. PMID: 31412242
7. Yoshino M. et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021. PMID: 33888596
8. Reyna K. et al. Intravenous infusion of nicotinamide adenine dinucleotide and nicotinamide riboside: a retrospective real-world pilot study. Frontiers in Aging, 2026. PMID: 41704678
9. U.S. Food and Drug Administration. FDA Reminds Compounders to Use Ingredients Suitable for Sterile Compounding. 2024. FDA.gov
10. U.S. Food and Drug Administration. Warning Letter to GenoGenix LLC. January 20, 2026. FDA.gov